
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is making significant progress in its clinical trials for gedatolisib, with completed enrollment in the Phase 3 VIKTORIA-1 trial and ongoing trials for HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer. The addition of Study 2 in the VIKTORIA-2 trial expands Celcuity's potential TAM to nearly all newly diagnosed US patients, and the subcutaneous formulation presents a potential evergreening opportunity. Positive topline results from the VIKTORIA-1 trial, reporting significant PFS improvements, suggest the potential for gedatolisib to become a top choice for patients in the second-line and beyond setting, and forecasted peak sales of around $4.5 billion could result in a significant increase in equity value and support a Buy rating.
Bears say
Celcuity is projected to have a negative net income for the foreseeable future and may require additional funding to continue their clinical trials. There is also no guarantee that the company will be able to secure favorable financing or partnerships. However, the recent positive results from the VIKTORIA-1 trial and upcoming ASCO presentation could potentially increase the company's value and addressable market for its lead candidate gedatolisib. Overall, there are some potential risks and uncertainties for Celcuity's future, but the positive results and potential market expansion make the company one to watch.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares